Together, the NKEV experiments demonstrated that cancer patient-derived NKEVs exert greater cytotoxic effects than control NKEVs, significantly reducing the cisplatin dose required for anti-tumor activity and, in PBMC co-culture assays, can enhance the recruitment of CD56+ cells. Here, NCAM1 is linked to cancer.